Article

Drug-Resistant Tuberculosis 2020: Where We Stand

2020-03-22

Abstract excerpt

The control of tuberculosis (TB) is hampered by the emergence of multidrug-resistant (MDR) Mycobacterium tuberculosis (Mtb) strains, defined as resistant to at least isoniazid and rifampin, the two bactericidal drugs essential for the treatment of the disease. Due to the worldwide estimate of almost half a million incident cases of MDR/rifampin-resistant TB, it is important to continuously update the knowledge on...

Identifiers and source

Literature Corpus work: 69017086-92cd-52ed-8fa4-9fe98eb9601f
DOI: 10.3390/app10062153

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Drug-Resistant Tuberculosis 2020: Where We StandDOI 10.3390/app10062153Read

Multidrug-resistant tuberculosis: a comprehensive review of pathogenesis, drug resistance, current treatment and future prospects.Semantic proximity Read

Drug-Resistant Tuberculosis: A Glance at Progress and Global Challenges.Semantic proximity Read

Drug resistance mechanisms and drug susceptibility testing for tuberculosis.Semantic proximity Read

Eradication of Drug-Tolerant Mycobacterium tuberculosis 2022: Where We StandSemantic proximity Read

Mechanisms of drug resistance in mycobacterium tuberculosisSemantic proximity Read

Multidrug-resistant tuberculosis.Semantic proximity Read

Mycobacterium tuberculosis: drug-resistance mechanisms.Semantic proximity Read

Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.Semantic proximity Read

[Tuberculosis].Semantic proximity Read

Drug‐resistant tuberculosis: Past, present, futureSemantic proximity Read

Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives.Semantic proximity Read

Tuberculosis Phenotypic and Genotypic Drug Susceptibility Testing and Immunodiagnostics: A ReviewSemantic proximity Read